669 related articles for article (PubMed ID: 17997386)
1. Targeting phosphoinositide 3-kinase: moving towards therapy.
Marone R; Cmiljanovic V; Giese B; Wymann MP
Biochim Biophys Acta; 2008 Jan; 1784(1):159-85. PubMed ID: 17997386
[TBL] [Abstract][Full Text] [Related]
2. PI3K/PTEN signaling in tumorigenesis and angiogenesis.
Jiang BH; Liu LZ
Biochim Biophys Acta; 2008 Jan; 1784(1):150-8. PubMed ID: 17964232
[TBL] [Abstract][Full Text] [Related]
3. Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast.
Rodríguez-Escudero I; Roelants FM; Thorner J; Nombela C; Molina M; Cid VJ
Biochem J; 2005 Sep; 390(Pt 2):613-23. PubMed ID: 15913452
[TBL] [Abstract][Full Text] [Related]
4. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
5. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.
Andersen JN; Sathyanarayanan S; Di Bacco A; Chi A; Zhang T; Chen AH; Dolinski B; Kraus M; Roberts B; Arthur W; Klinghoffer RA; Gargano D; Li L; Feldman I; Lynch B; Rush J; Hendrickson RC; Blume-Jensen P; Paweletz CP
Sci Transl Med; 2010 Aug; 2(43):43ra55. PubMed ID: 20686178
[TBL] [Abstract][Full Text] [Related]
6. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
[TBL] [Abstract][Full Text] [Related]
7. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease.
Oudit GY; Sun H; Kerfant BG; Crackower MA; Penninger JM; Backx PH
J Mol Cell Cardiol; 2004 Aug; 37(2):449-71. PubMed ID: 15276015
[TBL] [Abstract][Full Text] [Related]
8. Recent patents of gene sequences relative to the phosphatidylinositol 3-kinase/Akt pathway and their relevance to drug discovery.
Doepfner KT; Boller D; De Laurentiis A; Guerreiro AS; Marinov M; Arcaro A
Recent Pat DNA Gene Seq; 2007; 1(1):9-23. PubMed ID: 19075915
[TBL] [Abstract][Full Text] [Related]
9. Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.
Dan S; Okamura M; Seki M; Yamazaki K; Sugita H; Okui M; Mukai Y; Nishimura H; Asaka R; Nomura K; Ishikawa Y; Yamori T
Cancer Res; 2010 Jun; 70(12):4982-94. PubMed ID: 20530683
[TBL] [Abstract][Full Text] [Related]
10. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
11. PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.
Nozhat Z; Hedayati M
Mol Diagn Ther; 2016 Feb; 20(1):13-26. PubMed ID: 26597586
[TBL] [Abstract][Full Text] [Related]
12. PI3K-Akt pathway: its functions and alterations in human cancer.
Osaki M; Oshimura M; Ito H
Apoptosis; 2004 Nov; 9(6):667-76. PubMed ID: 15505410
[TBL] [Abstract][Full Text] [Related]
13. Development of an immunohistochemical protein quantification system in conjunction with tissue microarray technology for identifying predictive biomarkers for phosphatidylinositol 3-kinase inhibitors.
Isoyama S; Yoshimi H; Dan S; Okamura M; Seki M; Irimura T; Yamori T
Biol Pharm Bull; 2012; 35(9):1607-13. PubMed ID: 22975517
[TBL] [Abstract][Full Text] [Related]
14. Transient targeting of phosphoinositide 3-kinase acts as a roadblock in mast cells' route to allergy.
Collmann E; Bohnacker T; Marone R; Dawson J; Rehberg M; Stringer R; Krombach F; Burkhart C; Hirsch E; Hollingworth GJ; Thomas M; Wymann MP
J Allergy Clin Immunol; 2013 Oct; 132(4):959-68. PubMed ID: 23683463
[TBL] [Abstract][Full Text] [Related]
15. PTEN-deficient cancers depend on PIK3CB.
Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892
[TBL] [Abstract][Full Text] [Related]
16. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.
Weng LP; Smith WM; Dahia PL; Ziebold U; Gil E; Lees JA; Eng C
Cancer Res; 1999 Nov; 59(22):5808-14. PubMed ID: 10582703
[TBL] [Abstract][Full Text] [Related]
17. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
Fang J; Ding M; Yang L; Liu LZ; Jiang BH
Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
[TBL] [Abstract][Full Text] [Related]
18. Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy.
Yu K; Toral-Barza L; Shi C; Zhang WG; Zask A
Cancer Biol Ther; 2008 Feb; 7(2):307-15. PubMed ID: 18059185
[TBL] [Abstract][Full Text] [Related]
19. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
20. Reactivation of AKT signaling following treatment of cancer cells with PI3K inhibitors attenuates their antitumor effects.
Dufour M; Dormond-Meuwly A; Pythoud C; Demartines N; Dormond O
Biochem Biophys Res Commun; 2013 Aug; 438(1):32-7. PubMed ID: 23867821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
